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Routine clinical application of whole exome sequencing remains challenging due to difficulties in variant
interpretation, large dataset management, and workflow integration. We describe a tool named ClinLabGeneticist
to implement a workflow in clinical laboratories for management of variant assessment in genetic testing and
disease diagnosis. We established an extensive variant annotation data source for the identification of pathogenic
variants. A dashboard was deployed to aid a multi-step, hierarchical review process leading to final clinical
decisions on genetic variant assessment. In addition, a central database was built to archive all of the genetic
testing data, notes, and comments throughout the review process, variant validation data by Sanger sequencing
as well as the final clinical reports for future reference. The entire workflow including data entry, distribution of
work assignments, variant evaluation and review, selection of variants for validation, report generation, and
communications between various personnel is integrated into a single data management platform. Three case
studies are presented to illustrate the utility of ClinLabGeneticist. ClinLabGeneticist is freely available to academia
at http://rongchenlab.org/software/clinlabgeneticist.Background
Molecular genetic testing is playing an increasingly im-
portant role in medicine. Due in large part to the
breakthrough of genome and exome sequencing tech-
nologies, the scope of clinical genetic testing has been
expanded from its traditional niche in rare Mendelian
disorders to a broad application in complex disease and
personalized medicine [1, 2]. Currently, clinical genetic
testing is utilized for a variety of purposes including
follow-up to newborn screening for the identification of
genetic disease that may affect a child’s long-term health
or survival, carrier screening for inherited recessive and
X-linked diseases, diagnostic testing for symptomatic indi-
viduals, predictive testing of asymptomatic individuals for
late-onset and complex diseases, pharmacogenetic testing
for drug responses with respect to efficacy or adverse* Correspondence: lisa.edelmann@mssm.edu; rong.chen@mssm.edu
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article, unless otherwise stated.effects, and testing of tumor biopsies to determine somatic
alterations for cancer classification, prognosis, and devel-
opment of personalized treatment options [1].
There are a number of challenges in applying whole
exome sequencing (WES) in clinical genetic testing.
Although most clinical genetic testing laboratories follow
the guidelines from national and international agencies
such as American College of Medical Genetics (ACMG),
College of American Pathologists (CAP), and Clinical
and Laboratory Standard Institute (CLSI), tools are
lacking to bridge these guidelines and clinical practice.
In addition, there are a large number of variants of un-
certain significance (VUS). As basic research accelerates
with improved technology and more discoveries are
made toward the genetic basis of human diseases, it is
critical to incorporate the most updated and comprehen-
sive genetic variant findings into clinical genetic testing.
In addition, previously completed testing reports may
need to be updated when new information becomes avail-
able on the function and pathogenicity of the identifiede is distributed under the terms of the Creative Commons Attribution 4.0
ns.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
give appropriate credit to the original author(s) and the source, provide a
indicate if changes were made. The Creative Commons Public Domain
.org/publicdomain/zero/1.0/) applies to the data made available in this
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a complicated process, which requires efficient data
management and process management with seamless
coordination and communication between various
personnel. A final report for each patient is expected to
precisely summarize the current knowledge surround-
ing the variants and their clinical implication with
supporting evidence, and the report should be gener-
ated in a comprehensive fashion. Currently, although
many clinical laboratories use commercial tools to
annotate variants in a semi-automated fashion, variant
assessment still involves manual inspection of different
online databases and copy-paste of relevant content
into the report. Many laboratories still use Excel files to
manage variant datasets. As the volume of WES testing
increases, this practice is inefficient, error-prone, and
unscalable. Therefore, in order to facilitate the implemen-
tation of WES-based genetic testing, an integrative tool is
essential to provide a comprehensive data source for vari-
ant assessment, and to automate, therefore, enhance the
efficiency of the process and reduce potential errors that
may arise in handling large datasets.
There are several commercial tools currently available
for variant analysis and interpretation. For example, In-
genuity Variant Analysis tool by QIAGEN [3], Geneticist
Assistant by SoftGenetics [4], VarSeq by Golden Helix
[5], VarSim by Bina Technology [6], ANNOVAR Tute
annotation from Tute Genomics [7], and The Exchange
by NextCode [8] allow users to import VCF files after
initial processing of sequencing data, followed by variant
filtering based on data-related parameters such as sup-
porting sequence reads or allele frequency. Subsequently,
users can further explore the data to examine if the vari-
ants are present in various databases such as dbSNP [9]
for known polymorphisms and their population allele
frequencies, or in disease related variant databases such
as ClinVar [10], OMIM [11], HGMD [12], and COSMIC
[13]. Potential functional consequences of the variants
can also be assessed using methods such as SIFT [14],
PolyPhen [15], and SeqHBase [16, 17]. Most of these
tools also provide a genomic viewer for visualization of
variants and sequence alignment. Some of the tools,
such as NextCode’s The Exchange, even allow user-
controlled data sharing. However, most of these tools
are designed primarily for research purposes and others
do not meet all the needs of a clinical laboratory. Gen-
eInsight Suite is a tool developed to support use of
DNA-based genetic testing by clinical laboratories and
health providers [18]. However, it was primarily designed
for clinical variant data storage, variant classification,
and report generation.
Previously, we reported a comprehensive validation
study for WES implementation in the Genetic Testing
Laboratory at Mount Sinai [19]. We tested parametersthat measure the reproducibility of the sequencing plat-
form as well as the informatics pipelines. Our evaluation
focused on SNV and small indel detection for a single
workflow across multiple technical replicates. This study
validated the analytic performance of WES according to
the recommended guidelines [20], and established the
foundation of WES-based genetic testing at Mount Sinai.
In this report, we describe a tool named ClinLabGeneticist
specifically designed to enable and facilitate WES testing
in a clinical genetic laboratory setting. We have estab-
lished a comprehensive data repository for variant annota-
tion including all of the publicly available databases, to
our knowledge, for non-disease or disease-related variants.
This application provides a platform to automate data
management and process management for the highly
complex genetic testing workflow, significantly improving
the efficiency of clinical WES testing.
Implementation
WES and ClinLabGeneticist workflow
The overall WES workflow at Mount Sinai Genetic Test-
ing Laboratory is illustrated in Fig. 1. For whole exome
sequencing, genomic DNA was extracted from the periph-
eral blood samples of patients and exonic regions were
enriched by Agilent SureSelect XT Human All Exon V5
capture library. Massively parallel sequencing was per-
formed on an Illumina HiSeq2000/2500 with a 100 bp
paired-end protocol. The genome analysis pipeline or
GAP, which is based on the 1000 Genomes data analysis
pipeline and is composed from the widely-used open
source software projects including bwa, Picard, GATK,
snpEff, BEDTools, PLINK/SEQ, and custom-developed
software was used for variant calling and annotation [19].
VCF files generated by GAP were then uploaded into In-
genuity Variant Analysis tool (QIAGEN) for further vari-
ant filtering. Based on patients’ clinical and family history,
multiple analyses were performed in Ingenuity including
HGMD analysis (for searching disease-causing mutations
or DM reported in HGMD database), de novo analysis (for
searching de novo variants), dominant analysis (for domin-
ant inheritance pattern), recessive analysis, compound
heterozygous analysis (both for recessive inheritance and
X-linked patterns), and secondary finding analysis (based
on ACMG incidental finding gene list) [21]. Variant lists
generated by these Ingenuity analyses were then used as
input for the ClinLabGeneticist software. Users can also
upload input files directly into ClinLabGeneticist after
variant filtering using tools such as Cartagenia Bench
Suite [22] or the Clinical Sequence Analyzer (CSA) from
NextCode [23]. The input file format (Additional file 1:
Table S1) should include the following columns: chromo-
some number, chromosome coordinate, reference allele,
sample allele, gene symbol, transcript ID, nucleotide alter-
ation, amino acid alteration, SIFT functional prediction,
Fig. 1 WES workflow at Mount Sinai Genetic Testing Laboratory
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p-value, dbSNP ID, and 1000 genome allele frequency.
ClinLabGeneticist supports analysis of variants gener-
ated using various sequencing platforms including Ion
Torrent, Agilent, Nimblegen, and others.
The architecture and functionalities of ClinLabGen-
eticist are depicted in Fig. 2. Two dashboards were
designed for the administrators and the reviewers. The
dashboard for the administrators enables them to accom-
plish the following responsibilities: (1) Upload variant data
derived from a patient sample; generate a master table
with variant annotations automatically retrieved from our
annotation repository; select relevant annotation data-
bases for each variant; distribute variants to different
groups of reviewers; and notify reviewers of their tasksand deadlines. Each variant can be assigned to at least
two reviewers for independent review. (2) Examine the
results submitted by the reviewers, merge results, and
highlight discordant interpretations on the same variant
by different reviewers. (3) Set up reviewer group meet-
ings for discussion, resolve discrepancies in variant
interpretations, select variants for validation by Sanger
sequencing, and trigger the validation process. (4) Push
results to the laboratory director for final decisions on
what variants to report and their interpretations, and
generate variant tables for final reports.
The reviewers’ dashboard is designed to allow reviewers
to review the assigned variants, provide variant analysis re-
sults and interpretations through the dashboard, and
discuss with other reviewer assigned on the same variant.
Fig. 2 Architecture and functionalities of ClinLabGeneticist. a Administrator annotates and distributes variants to reviewers. b Reviewers review
variants and make a group decision. c Lab director confirms variants and generates report. d Administrator manages reviewers, archives variants,
queries recurrent variants, and retrieves history. e System management by system administrators
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notation every 30 s. The IGV viewer is integrated into
ClinLabGeneticist to display sequence alignment for visual
inspection of variants. Hyperlinks are set up for variant
annotations to their corresponding external databases (for
example, dbSNP, OMIM, ClinVar, and so on) upon which
the annotation is based. In addition, the chromosome
location of the variant is linked to the UCSC browser,
gene symbol is linked to the GeneCards website for more
detailed gene description, and each gene is linked to NCBI
PubMed for relevant literature. Integration of these links
and the IGV viewer provides tremendous convenience for
the reviewers so they can perform all required tasks within
the same software system without having to manually
launch different tools separately.
The system is managed by a system administrator
whose responsibilities include granting privileges, adding
or removing reviewers, and managing variant archives.
Variant annotation resources in ClinLabGeneticist
We developed a comprehensive variant annotation reposi-
tory. The included databases, datasets, and annotation
features are listed in Table 1 and Additional file 1: TableS2. They comprise publicly available databases for non-
disease (for example, dbSNP, 1000 genome, UK10K,
ESP6500 from NHLBI’s exon sequencing project, the
Wellderly project by Scripps Insititute, and ExAC data
from Exome Aggregation Consortium) or disease-
related (for example, HGMD, ClinVar, OMIM, and
UK10K disease) variants. In addition, data sources that
are not yet available to public are incorporated, such as
genotyping data from Mount Sinai Biobank, a biobank
established in 2007 in New York City with ethnically di-
verse participants [24], and in-house curated disease
variant database VarDi [25] based on manual curation
and literature mining. We also added datasets for func-
tional consequences of the variants such as dbNSFP and
pre-computed results of currently known genetic variants
using tools such as SIFT [14], PolyPhen [15], ANNOVAR
[7], SnpEff [26], and MutationAssessor [27].
Software implementation
ClinLabGeneticist is built on the Windows platform
(Window 7 and 8). Conventional client/server architec-
tures were utilized to support concurrent and multi-users.
Specifically, the machine with Windows operating system




dbSNP NCBI genetic variant database [9]
1000 Genome 1000 genome sequencing project [35]
ESP6500 Exome sequencing project by NHLBI [36]
UK10K control WGS cohorts of 4,000 people in UK [37]
Scripps
Wellderly
Sequencing of 2,000 healthy elderly
volunteers
[38]
ExAC Exome aggregation consortium [39]
dbNSFP Functional prediction and annotation of
non-synonymous SNVs
[40]
HGMD Human gene mutation database [12]
ClinVar Relationship between variants and human
disease phenotype
[10]
OMIM Online Mendelian Inheritance in Man [11]
UK10K disease WES of 6,000 patients with
neurodevelopment, obesity, and rare
diseases in UK
[37, 41]





Genotyping data from Biobank at Mount
Sinai
[24, 25]
VarDi In-house disease variants database [25]
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backend MySql database and performs data query, pro-
cessing, and management is the server. The server is
deployed in Linux. Major functions of the administrator
and the reviewers such as assignment distribution, variant
annotation, assignment combination, group meeting are
implemented on the Windows. All of the annotated and
reviewed variants by either administrator or reviewers are
saved in the database on the server. The client interface is
implemented by Visual Basic, HTML, and PHP.
We recommend the following hardware specifications
to run the software on the client side.
 Processor - Intel ® core™ i5-3470 @ 3.20 GHz (or
equivalent AMD)
 RAM - 4 GB (or higher)
 Hard drive - 120 GB 5,400 RPM hard drive
 Wireless (for laptops) - 802.11 g/n (WPA2 support
required)
 Operating system - Windows 7 or 8
Currently our backend MySql database is deployed on
Mount Sinai high performance computer system which
consist of 120 Dell C6145, two blade chassis nodes,
7,680 Advanced Micro Devices (AMD) 2.3 GHz Interla-
gos cores (64/node) and 64 compute cores in four
sockets, and 256 Gigabytes (GB)s of memory per node.
A detailed instruction on software installation and setupof internal server and backend databases is available as a
power point file on software’s homepage [28].
Patient consent and study approval
Informed consent for clinical exome sequencing was
obtained from all patients and/or their guardians. Pa-
tients assented to have their data used anonymously for
research in all cases as per New York State Department
of Health requirements for informed consent.
Results and discussions
A comprehensive genetic variant data repository
Our variant data repository included more than 400,000
variants at approximately 360,000 variant sites from more
than 10 databases (Table 1). The total number of samples
with whole genome or exome sequencing data from these
databases is approximately 82,000, with an additional
90,000 genotyped individuals.
Automation of clinical genetic testing process using
ClinLabGeneticist
A key feature of ClinLabGeneticist is the implementa-
tion of dashboards to automate the entire workflow.
Figure 3 shows selected screenshots of the administra-
tors’ dashboard and some of the functionalities con-
trolled by the dashboard. The dashboard (Fig. 3a) allows
the administrators to upload the data (Fig. 3b), distribute
the assignments with the defined timeline (Fig. 3c), high-
light discordant variant evaluation results by individual
reviewers (Fig. 3d), record decisions on variant interpreta-
tions and decisions on downstream validation by Sanger
sequencing (Fig. 3e), and finally generate a tables of
variants for the clinical report (Fig. 3f). Under hardware
specification described in the software implementation
section, it takes less than 10 min for an administrator to
upload and annotate one variant file from WES. Annota-
tion databases (Table 1) are not downloaded and stored
on local servers. Instead, a link to the original database
repository is provided so the administrator will always
retrieve the latest annotations from each database.
Reviewers’ dashboard and some of its functionalities
are illustrated in Fig. 4. The dashboard (Fig. 4a) allows
each reviewer to view a list of variants assigned by the
administrator using the annotation databases selected by
the administrator (Fig. 4b), and enables reviewers to
examine relevant variant annotation data sources and
references with external links in order to assess variant
pathogenicity and disease association (Fig. 4c). Upon
completion of evaluation, for each variant, the reviewers
make a call at the gene level regarding how the pheno-
type of the patient relates to the disease associated with
this gene (Table 2a). This is followed by a subsequent
call at the variant level regarding variant pathogenic cat-
egories (Table 2b). Variant annotations from different
Fig. 3 Screen shots of the administrators’ dashboard. (a) Dashboard, (b) functionalities controlled by the dashboard such as data upload, (c) distribute
work assignments, (d) merge data table, (e) validation of variants by sanger sequencing, and (f) selection of variants to generate final reports
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depending on circumstances. For example, ClinVar,
HGMD and OMIM annotations are critical to determine
variant pathogenicity. Variant allele frequencies in 1000
genome and ExAC are more important parameters when
variants are called benign. Based on these two calls, the
ClinLabGeneticist will take the following actions for the
variant based on an internally developed logic (Table 3):
report and proceed to validation by Sanger sequencing,
report without Sanger sequencing, or do not report. The
reviewers’ dashboard also allows each reviewer to
browse historical assignments and review results stored
in the database (Fig. 4d).After ClinLabGeneticist was launched, we have evalu-
ated more than 17,000 variants in 245 genes associated
with 53 diseases. For most variants that lack clear evi-
dence as pathogenic variants, it takes only 1–2 min to
complete the review process using ClinLabGeneticist.
For those variants with substantial annotation and litera-
ture reports, the maximal time to complete the review
process is approximately 15 min because all relevant
information is displayed by ClinLabGeneticist with ex-
ternal links and the IGV viewer automatically launched,
allowing the reviewers to navigate the information with
ease. Before ClinLabGeneticist was developed, variant
Excel files were generated and distributed to each of the
Fig. 4 Screen shots of the reviewers’ dashboard. (a) Dashboard, (b) functionalities controlled by the dashboard such as display assigned variant
lists, (c) review variants, and (d) access historic assignments and results
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laboratory directors or second reviewers will have to
consolidate and compare first reviewers’ assessment to
prioritize variants for follow-up studies such as Sanger
validation and categorization for final reporting. This
manual workflow was transformed by the implementation
of ClinLabGeneticist to become automated and therefore
reduced the administrative effort by at least 50 %. In
addition, all of the variants are annotated in ClinLabGen-
eticist in a fully customized manner which is essential to
improve overall work efficiency and accuracy in a clinical
lab. The reviewers will not need to search for annotations
in different public or private databases manually. More
importantly, most of the public or private variant data-
bases are not designed for clinical use and they have to be
curated and customized for clinical implementation,
which can be accomplished in ClinLabGeneticist. In the
following section, we present three case studies to further
illustrate the utility of ClinLabGeneticist. De novo, reces-
sive, compound heterozygous, and secondary variants in
each case were analyzed. Described in Additional file 1:
Table S3 are the number of variants at each step of the
process, for example, concordant and discordant calls by
different reviewers, decisions on variant report and Sanger
sequencing validation, and variant reporting in various
categories (primary, supplementary, and secondary find-
ing). Detailed variant list for each of the three cases are
provided in Additional file 1: Table S4–S6, respectively.Case study 1
Patient 1 was diagnosed with congenital erythropoietic
porphyria (CEP) at the age of 5 months by biochemical
testing and the diagnosis was later confirmed by DNA
analysis showing homozygosity for the UROS C73R mu-
tation, which is known to cause a severe phenotype. The
patient had a bone marrow transplantation at 2 years of
age due to transfusion-dependent hemolytic anemia and
severe cutaneous involvement associated with CEP.
However, the patient also had several other features that
were inconsistent with the diagnosis of CEP, including
developmental delay, congenital glaucoma, complicated
retinal and ocular problems, and facial dysmorphisms.
Due to the many unexplained anomalies, the patient was
evaluated by a clinical geneticist in 2012. Array CGH
was normal and molecular testing for Stickler syndrome
revealed a heterozygous variant of uncertain significance
in the COL11A1 gene. However, these tests were per-
formed on peripheral blood likely reflective of the bone
marrow donor’s results given the complete engraftment
from past transplantation.
The patient was evaluated at Mount Sinai and speci-
mens were submitted to the Mount Sinai Genetic Test-
ing Laboratory in February 2014 for exome sequencing
on fibroblasts derived from the patient’s skin biopsy
and blood samples from both parents. The sequence
data were analyzed as a trio, and variants analysis was
performed using ClinLabGeneticist software based on
Table 2 Criteria for assessment of disease association at gene (a) and at variant (b) level
a. Is phenotype applicable to this case (at gene level)
Option Where to look When to choose
Yes OMIM, HGMD, PubMed Disease clinical features match patient’s phenotype
Uncertain/possibly OMIM, HGMD, PubMed Disease clinical features partially overlap with patient’s
phenotype
No (clearly unrelated) OMIM, HGMD, PubMed No overlapping phenotype, totally different disease
No/little phenotypic evidence available OMIM, HGMD, PubMed Phenotypic evidence was only found in few low-quality papers,
or only from association studies, or only somatic mutations were
reported
de novo - No/little phenotypic evidence (chose for
variants from de novo filter only)
OMIM, HGMD, PubMed Same as ‘No/little phenotypic evidence available’, but only for de
novo variants
Reportable secondary finding OMIM, HGMD, PubMed Depends on patient’s requirement, mostly for genes associated
with actionable diseases. Not limit to genes in ACMG guideline.
If the patient does NOT want secondary findings, do NOT
choose this option
b. Interpretive category (at variant level except deleterious VUS)
Option Where to look When to choose
Benign 1000 Genomes, EVS, ExAC Allele frequency >1 % for recessive or X-linked patterns. And for
X-linked pattern, at least several hemizygous males should be
reported in the database. Or allele frequency >0.1 % for
dominant or de novo patterns
Likely benign UCSC genome browser Deletion/insertion of 1–2 aa in a repeat region composed of at
least 8 aa repeats
Intronic-likely benign UCSC genome browser,
HGMD, ClinVar
The nomenclature for all transcripts indicates that the change is
intronic, but not in canonical splice sites (−1, −2, +1, or +2),
except variants reported in HGMD or ClinVar as pathogenic/likely
pathogenic
VUS Variant which does not fit other categories




Variant assumed to disrupt gene function (nonsense, frameshift,
canonical splice sites, and so on), but in a gene with no/little
phenotype evidence available
Likely pathogenic UCSC genome browser,
ACMG guideline
Has not been reported before, but is assumed to disrupt gene
function (nonsense, frameshift, canonical splice sites, and so on).
Or variant which meets ACMG guideline
Pathogenic HGMD, ClinVar, OMIM Well-established disease-causing mutation by previous reports
Mapping error UCSC genome browser,
IGV, Ingenuity
Variant in segmental duplication or repeat region, and mapping
quality/coverage is low. Generally you can see many variant calls
in the same region. Also pay attention to complex variants such
as large deletions/insertions and indels, please check IGV
because nomenclature could be wrong
CompoundHet error Ingenuity Only 1 non-benign variant found in a gene. Only use for variants
that pass through the Compound Het filter
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recessive. ClinLabGeneticist was used in this study to
evaluate seven compound heterozygous, 22 recessive,
four de novo, and 15 secondary variants and generate a
clinical report. From the sequencing data, a homozy-
gous pathogenic mutation, c.217T>C was identified in
exon 4 of the UROS gene resulting in an amino acid
change p.C73R. Mutations in UROS cause autosomal
recessive congenital erythropoietic porphyria (MIM:
263700, [29]). This variant has been reported as the
most frequent mutation found in CEP (CM900225 in
HGMD database, RCV000003948.2 in ClinVar database,rs121908012 in dbSNP database). Sanger sequencing of
DNA from the trio confirmed that the mutation was
homozygous in the patient and that each of the parents
was a heterozygous carrier for this variant. Therefore, the
homozygous state of this variant was interpreted as a
pathogenic.
Two other variants were also reported from the study.
A de novo heterozygous variant of uncertain significance,
c.2855G>T was identified in the last exon of the INPP4A
gene resulting in an amino acid change p.R952L. INPP4A
has not been described as a disease-related gene with sub-
stantial evidence and there is limited information in the
Table 3 Logic for variant reporting and validation by Sanger sequencing









de novo - No/little
phenotypic evidence (chose
for variants from de novo
filter only)
Benign Do not report Do not report Do not report Do not report Do not report Do not report
Likely benign Report & Sanger Do not report Do not report Report & Sanger Report Report & Sanger
Intronic-likely benign Report & Sanger Do not report Do not report Report & Sanger Do not report Do not report
VUS Report & Sanger Do not report Do not report Report & Sanger Report Report & Sanger
Deleterious VUS













Report as VUS & Sanger
Likely pathogenic Report & Sanger Need discussion Report as
secondary &
Sanger




Error - please change to
Deleterious VUS
Pathogenic Report & Sanger Need discussion Report as
secondary &
Sanger




Error - please change to
Deleterious VUS
Mapping Error Investigate further
via Sanger
Do not report Do not report Need discussion Do not report Do not report
CompoundHet error Investigate further
via Sanger
Do not report Need discussion Need discussion Do not report Error - not compound het
Wang et al. Genome Medicine  (2015) 7:77 Page 9 of 12literature regarding its function. It has been suggested that
INPP4A plays a role in brain development as targeted
disruption of the Inpp4a gene in mice leads to neurode-
generation in the striatum, the input nucleus of the basal
ganglia that has a central role in motor and cognitive
behaviors [30]. The c.2855G>T variant in INPP4A is pre-
dicted to be damaging by SIFT and probably damaging by
PolyPhen-2. Sanger sequencing of DNA extracted from
the patient and both parents confirmed that the variant
occurred de novo. A second de novo heterozygous variant
of uncertain significance, c.985G>A was identified in exon
11 of the RANBP3 gene resulting in an amino acid change
p.E329K. RANBP3 has not been described as a disease-
related gene with substantial evidence and there is limited
information in the literature regarding its function. The
variant is predicted to be damaging by SIFT and possibly
damaging by PolyPhen-2. Sanger sequencing of DNA
extracted from the patient and both parents confirmed
that the variant occurred de novo. This variant was also
interpreted to be of uncertain significance.
In addition to the above three variants, seven com-
pound heterozygous variants were also reported in a
supplementary table. For three of these seven variants,
the initial review by two independent reviewers resulted
in discrepant calls. In two cases, one reviewer called the
variant ‘VUS’ while the other reviewer assigned the vari-
ant into the ‘mapping error’ category. In the third case,
one reviewer called the variant ‘likely pathogenic’ andthe other reviewer called the same variant ‘VUS’. Upon
further examination and discussion in the group meet-
ing, it was determined that all three variants should be
called ‘VUS’ and should be reported.
In summary, exome sequencing-based genetic testing
confirmed the homozygous pathogenic mutation p.C73R
despite reported complete engraftment of donor bone
marrow which should have precluded a positive result.
No variants were identified that explained the patient’s
other abnormalities though reanalysis could lead to re-
assignment of variant categories based on new data in
the future.
Case study 2
Patient 2 had significant developmental delay and some
dysmorphic features. Previous chromosome and Array
CGH analysis had not revealed any abnormalities. DNA
was also tested by a targeted gene panel for autism in
the Mount Sinai Medical Genetics Testing Laboratory,
but no pathogenic mutation was detected. Additional
metabolic screening test results were negative.
In light of the negative metabolic and genetic testing
workup, whole exome sequencing was performed on
DNA extracted from the patient and the parents. The se-
quence data were analyzed as a trio, and variants analysis
was performed using ClinLabGeneticist software based on
the following inheritance patterns: de novo, autosomal
recessive. A de novo variant of uncertain significance was
Wang et al. Genome Medicine  (2015) 7:77 Page 10 of 12identified in exon 31 of the PPFIA2 gene, NM_0012
20473.2:c.133A>G, p.Val1241Ile (hg19 Chr12:81653434).
PPFIA2 has not been described as a disease-related gene
with substantial evidence. This variant has not been re-
ported in any public population variant database and is pre-
dicted to be a ‘tolerated’ change by SIFT in silico analysis.
Sanger sequencing of DNA extracted from the patient and
both parents confirmed that the variant occurred de novo.
In addition, this variant was not detected in the patient’s
unaffected sibling.
Case study 3
Patient 3 is a 7-year-old boy with developmental delay.
He had some autistic features including poor eye con-
tact, impairment in social interaction, impairment in
communication, and repetitive and stereotypic behav-
iors. He also had a 5-year-old brother with developmen-
tal delay. Whole exome sequencing was performed on
DNA isolated from peripheral blood samples of the
patient and his parents. The sequence data were ana-
lyzed as a trio, and variants analysis was performed using
ClinLabGeneticist software based on the following inher-
itance patterns: de novo, autosomal recessive and X-
linked, and two de novo variants were identified.
The first de novo variant was identified in exon 32 of the
PCNXL2 gene, NM_014801.3: c.5626C>T, p.Arg1876Cys
(hg19 Chr1:233134162). PCNXL2 has not been described
as a disease-related gene and there is limited information
regarding its function. The variant is predicted to be dam-
aging by SIFT and benign by PolyPhen-2. Sanger sequen-
cing of DNA extracted from the patient, his parents and
brother confirmed that the mutation occurred de novo.
The second de novo variant was identified in exon 6 of
the RPS2 gene, NM_002952.3: c.623C>T, p.Pro208Leu
(hg19 Chr16:2012584). RPS2 encodes a ribosomal protein
that is a component of the 40S subunit. It has not been
described as a disease-related gene and there is limited in-
formation regarding function, although recently it has
been reported that RPS2 is involved in dendritic spine
maturation in rat hippocampal neurons [31]. The variant
is predicted to be damaging by SIFT and benign by
PolyPhen-2. Sanger sequencing of DNA extracted from
the patient, his parents and brother confirmed that the
mutation occurred de novo. Both de novo variant were
interpreted to be of uncertain significance.
Conclusions
Advancement of next generation sequencing technolo-
gies has provided an unprecedented opportunity in
medicine, and we have entered a new era of genetic and
genomic testing. However, a number of barriers need to
be overcome before the full potential of WES in disease
diagnosis and personalized medicine can be fully real-
ized. A constant challenge in clinical genetic testing andmolecular diagnosis is to interpret the clinical signifi-
cance of variants with high confidence. It has been
reported that some literature-annotated pathogenic vari-
ants are not truly ‘pathogenic’ [32, 33], and the issue is
further manifested when large population exome data
are examined [34]. Many variants in known disease
genes that have been previously identified in specific
disease cohorts occur at frequencies that are too high to
support pathogenicity. Currently, there is no single
comprehensive database with rigorously curated disease
pathogenic variants. Therefore, it is critical to include
all of the available variant annotation databases when
genetic testing results are examined to assess their
pathogenicity. Many commercially available variant
analysis tools only include the most-commonly used
population variant databases such as dbSNP and 1000
Genomes, or disease variant databases such as OMIM,
HGMD, and ClinVar. ClinLabGeneticist incorporates to
our knowledge, all publicly available variant databases,
providing an extremely comprehensive genetic variant
resource. Another issue in clinical genetic testing is the
complexity of the process.
A unique feature of ClinLabGeneticist is that we im-
plemented a logic table for variant interpretation at
both gene level and variant level (Table 2). In the vari-
ant review process, it is first determined if the patient’s
phenotype matches clinical features of the disease asso-
ciated with the gene harboring the variant. Then patho-
genicity of the variant is assessed. Decisions on variant
validation and reporting are made based on both gene
level and variant level assessments (Table 3). In con-
trast, currently available tools only allow variant level
evaluation and these tools are more suitable for panel-
based genetic testing where only known disease genes
are tested. Clearly, ClinLabGeneticist is designed to
enable a more comprehensive WES-based genetic test-
ing. Another important feature of ClinLabGeneticist is it
facilitates parallel variant review by multiple reviewers, in-
cluding distributing variants to different reviewers, entry
of variant analysis results by the reviewers, examining
results by the administrators, and decision-making on
final reporting. This complex process is managed more
efficiently by ClinLabGeneticist than currently available
tools.
In most clinical genetic laboratories, data management
and process management efficiency is suboptimal, with
many tasks handled manually. ClinLabGeneticist provides
a platform to streamline and automate the workflow, not
only significantly improving the efficiency and scalability,
but also making the entire process less error-prone. We
are currently generating WES data for an average of 30
trios per month and this scale can be readily handled by
ClinLabGeneticist. We do not anticipate any technical
issues if the number of WES-based testing increases to
Wang et al. Genome Medicine  (2015) 7:77 Page 11 of 12even several hundred trios per month. The challenge
though is more reviewers are needed for variant assess-
ment as the scale of WES goes up.
We also recognize the limitation of ClinLabGeneticist.
Although patient clinical information is taken into consid-
eration during variant assessment, it has not been incor-
porated into ClinLabGeneticist’s workflow. A new version
of the software is being developed to improve on this
aspect. In addition, currently ClinLabGeneticist is not
amenable to analysis of disease associated copy number
variation (CNV) or chromosome structural variation (SV).
Therefore, although whole genome sequencing (WGS)
platform is still supported by ClinLabGeneticist, only
single nucleotide variants (SNVs) and small insertions/de-
letions would be analyzed. We will certainly revise the
workflow and the tool when more clear guidelines on
CNV and SV assessment become available.
Availability and requirements
Project name: ClinLabGeneticist
Project home page: http://rongchenlab.org/software/
clinlabgeneticist
Operating system(s): Windows
Programming language: Visual Basic, PHP, HTML
Other requirements: mySql
License: GNU, HGMD
Any restrictions to use by non-academics: please contact
the authors
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Additional file 1: Table S1. A sample variant input file for
ClinLabGeneticist. Table S2. Variant annotation databases and features.
Table S3. Summary statistic of variant review process for the three
case studies. Table S4. Variant list for case 1. Table S5. Variant list for
case 2. Table S6. Variant list for case 3. (XLSX 42 kb)
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